Crizanlizumab vs Nivolumab

Crizanlizumab vs Nivolumab: Overview

This comparison examines the pharmacological differences between Crizanlizumab and Nivolumab.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Nivolumab — 27 days.

Chemical Properties

Type: Crizanlizumab — Antibody; Nivolumab — Antibody.